Valuation: Xvivo Perfusion AB

Market Cap 6.49B 644M 584M 540M 487M 918M 60.76B 951M 2.57B 32.46B 2.42B 2.37B 103B P/E 2026 *
59.5x
P/E 2027 * 46x
Enterprise Value 6.37B 632M 573M 530M 478M 901M 59.63B 933M 2.52B 31.85B 2.37B 2.32B 101B EV / Sales 2026 *
6.44x
EV / Sales 2027 * 5.33x
Free-Float
77.41%
Yield 2026 *
-
Yield 2027 * -
1 day+1.58%
1 week+4.30%
Current month+0.49%
1 month-6.11%
3 months-30.22%
6 months-26.74%
Current year+10.40%
1 week 197.2
Extreme 197.2
210
1 month 192.9
Extreme 192.9
235.6
Current year 171.8
Extreme 171.8
314.8
1 year 160.1
Extreme 160.1
314.8
3 years 160
Extreme 160
547
5 years 127.8
Extreme 127.8
547
10 years 70.3
Extreme 70.3
547
Manager TitleAgeSince
Chief Executive Officer 51 2022-09-26
Director of Finance/CFO 41 2020-11-30
Chief Operating Officer 61 2022-11-30
Director TitleAgeSince
Chairman 67 2018-04-26
Director/Board Member 62 2016-04-30
Director/Board Member 65 2021-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
7/21/26 Buy

Director

1,643 0.0052%
7/21/26 Buy

Director

2,007 0.0064%
3/20/26 Buy

Chief Financial Officer

300 0.0010%
Change 5-day change 1-year change 3-year change Capi.($)
+1.58%+4.30%+25.53%-18.90% 644M
+1.18%-1.28%-16.90%+11.78% 188B
+1.85%+1.04%+7.29%+41.70% 126B
-0.88%-4.98%-14.52%+9.40% 118B
+1.36%-5.91%-42.82%+1.32% 92.48B
+2.96%+7.64%-0.80%+84.71% 68.51B
+1.08%+2.90%+12.95%-6.56% 59.39B
+0.89%+4.17%+2.07%+55.03% 55.48B
-0.68%+6.83%-1.08%+55.36% 49.62B
+1.79%+0.10%-0.55%-8.36% 35.17B
Average +1.11%+1.00%-2.88%+22.55% 79B
Weighted average by Cap. +1.04%-0.38%-9.02%+24.72%

Financials

2026 *2027 *
Net sales 988M 98.15M 88.94M 82.27M 74.23M 140M 9.25B 145M 392M 4.94B 368M 361M 15.69B 1.2B 119M 108M 99.79M 90.04M 170M 11.23B 176M 475M 6B 447M 437M 19.03B
Net income 109M 10.82M 9.81M 9.07M 8.19M 15.43M 1.02B 15.97M 43.22M 545M 40.62M 39.76M 1.73B 141M 14.03M 12.71M 11.76M 10.61M 19.99M 1.32B 20.69M 56M 706M 52.63M 51.52M 2.24B
Net Debt -122M -12.07M -10.94M -10.12M -9.13M -17.21M -1.14B -17.81M -48.2M -608M -45.31M -44.35M -1.93B -104M -10.33M -9.36M -8.66M -7.81M -14.72M -974M -15.24M -41.24M -520M -38.76M -37.94M -1.65B
Projected Income Statement - Annual - Xvivo Perfusion AB
Logo Xvivo Perfusion AB
Xvivo Perfusion AB is a Sweden-based medical technology company focused on developing optimized solutions for organ, tissue and cell preservation in connection with transplantation. The Company operates in two segments: Durable goods and Non-Durable goods. The Durable goods segment comprises sale and rental income from XVIVO Perfusion System (XPS) machines. The Non-Durable goods segment implies revenue from the sale of products and services that are solutions and disposable items. The Company’s product portfolio consists of Perfadex, STEEN Solution, XPS, XPS Disposable Kit, XVIVO Lung Cannula Set, XVIVO Organ Chamber, XPS PGM Disposable Sensors and Silicone Tubing Set. The Company markets its products in Europe, Asia, Middle East, and North & South America.
Employees
207
Date Price Change Volume
26-11-13 SEK 206.00 +1.58% 99,031
26-11-12 SEK 202.80 -1.55% 68,399
26-11-11 SEK 206.00 +0.98% 86,839
26-11-10 SEK 204.00 +1.59% 70,458
26-11-09 SEK 200.80 +1.67% 60,457
Trader
Investor
Global
Quality
ESG MSCI
AAA
MarketScreener Ratings - Xvivo Perfusion AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
206.00SEK
Average target price
304.00SEK
Spread / Average Target
+47.57%
  1. Stock Market
  2. Stocks
  3. XVIVO Stock